Erasca's Pan-RAS Inhibitor ERAS-0015 Gains FDA Fast Track for Metastatic Pancreatic Cancer — Erasca, Inc.

Event summary

FDA grants Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma on August 24, 2026.
Phase 1 trial AURORAS-1 shows 57% overall response rate in 2L+ KRAS G12X pancreatic cancer patients.
Three potentially registration-enabling trials planned for pancreatic and lung cancers.
Additional Phase 1 monotherapy and combination data expected in H1 2027.

The big picture

Erasca's Fast Track designation for ERAS-0015 underscores the urgent need for new therapies in metastatic pancreatic cancer, a field with limited treatment options. The designation accelerates the development of pan-RAS inhibitors, a promising class of drugs designed to comprehensively shut down the RAS/MAPK pathway. Success in this area could position Erasca as a leader in precision oncology, particularly if ERAS-0015 demonstrates sustained efficacy in larger trials.

What we're watching

Clinical Efficacy: Whether ERAS-0015 can sustain its 57% response rate in larger, potentially registration-enabling trials.
Regulatory Pathway: The pace at which FDA will expedite the review process under Fast Track Designation.
Competitive Positioning: How Erasca differentiates ERAS-0015 against competitors like Revolution Medicines in the RAS inhibitor space.